2022 Biotech Growth Stage (pre-series B)

Pharma Partnering With Otsuka Pharmaceutical

• Otsuka: 100 years of Innovation for Better Health Worldwide
• Leveraging Internal Capabilities and Collaborations to Build a Global Pharma Business
• Why Collaborate with Otsuka in Neuroscience, Kidney or Autoimmune Diseases?

Sahil Kirpekar, Head of Business Development, Otsuka Pharmaceutical
Armin Rump, Associate Director, Global Business Development, Otsuka Pharmaceutical

CNS and the Market -- What is New in the Pipeline and in Deal Activity?

A few years ago, a “quiet revolution” was taking place in central nervous system (CNS) therapeutics: Companies large and small started to put more resources into CNS research, developing novel therapies for debilitating neurological and psychiatric diseases. The outcome of that development underpinned higher deal and investment activity. However, in the first half of 2022, CNS company stocks fell by 28%. Biotech and pharma company representatives as well as specialised investors will discuss the current state of affairs of CNS drug development: What’s on the horizon?

• From rare neurological to large psychiatric indications. What are the most significant new developments in CNS therapeutics?
• Progress in precision neuropsychiatry and biomarker development
• What is next for CNS drugs? Predictions for the next 10 years

Moderator: Olga Krylova, Director, Global Business Development, Otsuka Pharmaceutical
Jenny Barnett, CEO, Monument Tx
Dima Kuzmin, Managing Partner, 4BIO Capital
Carlos Buesa, CEO, ORYZON

Close of Investival Showcase

Awards & Gala Dinner
- Separate ticket required
- Find out more